S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
NFLX   379.24 (+5.32%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
NFLX   379.24 (+5.32%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
NFLX   379.24 (+5.32%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
NFLX   379.24 (+5.32%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
Log in

NYSEAMERICAN:OGEN - Oragenics Stock Price, Forecast & News

$0.53
-0.04 (-7.02 %)
(As of 02/26/2020 04:00 PM ET)
Today's Range
$0.52
Now: $0.53
$0.57
50-Day Range N/A
52-Week Range
$0.35
Now: $0.53
$0.99
Volume891,477 shs
Average Volume1.10 million shs
Market Capitalization$24.45 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring chemical agent for use in weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013; a license agreement with LPThera LLC to develop LPT3-04; and a license agreement Texas A&M University System for access to new homologs of the lantibiotic MU1140 and other lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:OGEN
CUSIPN/A
Phone+1-813-2867900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees6
Market Cap$24.45 million
Next Earnings Date4/3/2020 (Estimated)
OptionableNot Optionable

Receive OGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter.


Oragenics (NYSEAMERICAN:OGEN) Frequently Asked Questions

What is Oragenics' stock symbol?

Oragenics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OGEN."

When did Oragenics' stock split? How did Oragenics' stock split work?

Oragenics's stock reverse split before market open on Monday, January 22nd 2018. The 1-10 reverse split was announced on Monday, January 8th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 19th 2018. An investor that had 100 shares of Oragenics stock prior to the reverse split would have 10 shares after the split.

How were Oragenics' earnings last quarter?

Oragenics Inc (NYSEAMERICAN:OGEN) released its quarterly earnings results on Wednesday, August, 14th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.03. View Oragenics' Earnings History.

When is Oragenics' next earnings date?

Oragenics is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Oragenics.

What price target have analysts set for OGEN?

1 brokers have issued 12-month price objectives for Oragenics' shares. Their forecasts range from $2.00 to $2.00. On average, they anticipate Oragenics' share price to reach $2.00 in the next twelve months. This suggests a possible upside of 277.4% from the stock's current price. View Analyst Price Targets for Oragenics.

What is the consensus analysts' recommendation for Oragenics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oragenics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oragenics.

Has Oragenics been receiving favorable news coverage?

Media stories about OGEN stock have trended very negative recently, InfoTrie reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Oragenics earned a news impact score of -3.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Oragenics.

Are investors shorting Oragenics?

Oragenics saw a decline in short interest in the month of January. As of January 15th, there was short interest totalling 1,300,000 shares, a decline of 8.5% from the December 31st total of 1,420,000 shares. Based on an average daily volume of 561,800 shares, the short-interest ratio is presently 2.3 days. Approximately 3.1% of the company's shares are short sold. View Oragenics' Current Options Chain.

Who are some of Oragenics' key competitors?

What other stocks do shareholders of Oragenics own?

Who are Oragenics' key executives?

Oragenics' management team includes the folowing people:
  • Dr. Alan F. Joslyn, Pres, CEO & Director (Age 60)
  • Mr. Michael O. Sullivan CPA, CFO, Sec. & Treasurer (Age 63)
  • Dr. Martin Handfield, Sr. VP of Discovery Research (Age 48)
  • Dr. Raman Bedi, Chairman of International Scientific Advisory Board and Sr. Consultant

Who are Oragenics' major shareholders?

Oragenics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Barclays PLC (0.73%), Renaissance Technologies LLC (0.31%), Virtu Financial LLC (0.21%) and UBS Group AG (0.14%). Company insiders that own Oragenics stock include Family Lp Koski and Robert C Koski. View Institutional Ownership Trends for Oragenics.

Which major investors are buying Oragenics stock?

OGEN stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Virtu Financial LLC, Barclays PLC and UBS Group AG. View Insider Buying and Selling for Oragenics.

How do I buy shares of Oragenics?

Shares of OGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Oragenics' stock price today?

One share of OGEN stock can currently be purchased for approximately $0.53.

How big of a company is Oragenics?

Oragenics has a market capitalization of $24.45 million. Oragenics employs 6 workers across the globe.View Additional Information About Oragenics.

What is Oragenics' official website?

The official website for Oragenics is http://www.oragenics.com/.

How can I contact Oragenics?

Oragenics' mailing address is 4902 Eisenhower Blvd Ste 125, TAMPA, FL 33634-6342, United States. The biotechnology company can be reached via phone at +1-813-2867900.


MarketBeat Community Rating for Oragenics (NYSEAMERICAN OGEN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  119 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  231
MarketBeat's community ratings are surveys of what our community members think about Oragenics and other stocks. Vote "Outperform" if you believe OGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel